⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024690 | 1.00 | — | — | |
| SCHEMBL22920101 | 1.00 | — | — | |
| Ammonia Solution, Strong SCHEMBL28310281 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3600107 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6870898 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL29288193 | 0.97 | — | — | |
| SCHEMBL221055 | 0.87 | — | — | |
| SCHEMBL572346 | 0.87 | — | — | |
| SCHEMBL240170 | 0.87 | — | — | |
| Hydrochloric Acid SCHEMBL25236164 | 0.85 | GLI1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115256-A1 | HUMAN AMYLIN ANALOG, AND DERIVATIVE THEREOF AND USE THEREOF | HANGZHOU SCIWIND BIOSCIENCES CO., LTD. (CN) | 2026-04-30 | — | — | US | disclosed |
| US-20260042771-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2026-02-12 | — | — | US | disclosed |
| EP-4570795-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | Astellas Pharma, Inc. (JP) | 2025-06-18 | — | — | EP | disclosed |
| EP-4534553-A1 | HUMAN AMYLIN ANALOG, AND DERIVATIVE AND USE THEREOF | Hangzhou Sciwind Biosciences Co., Ltd. (CN) | 2025-04-09 | — | — | EP | disclosed |
| CN-119604495-A | Heterocyclic compounds for inducing G12V mutant KRAS protein degradation | 安斯泰来制药株式会社 | 2025-03-11 | — | — | CN | disclosed |
| WO-2024034593-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12V MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-02-15 | — | — | WO | disclosed |
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-20110288065-A1 | AMINOPYRAZINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| WO-2011025982-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011000855-A1 | 2-CARBOXAMIDE CYCLOAMINO UREAS USEFUL AS PI3K INHIBITORS | NOVARTIS AG (CH) | 2011-01-06 | — | — | WO | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| US-20110003786-A1 | 2-Carboxamide Cycloamino Ureas | NOVARTIS AG | 2011-01-06 | — | — | US | disclosed |
| EP-2240475-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | Novartis AG (CH) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009080694-A1 | THIAZOLE DERIVATIVES USED AS PI 3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163469-A1 | Organic Compounds | NOVARTIS AG | 2009-06-25 | — | — | US | disclosed |
| WO-2007023382-A2 | PYRIMIDINE AMINO PYRAZOLE COMPOUNDS, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2007-03-01 | — | — | WO | disclosed |